Your browser doesn't support javascript.
loading
The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura, Masanari; Kim, Jeong-Hwan; Aoyama, Haruki; Hoshino, Yujiro; Fukumura, Hidenobu; Nakakaji, Rina; Sato, Itaru; Ohtake, Makoto; Akimoto, Taisuke; Narikawa, Masatoshi; Tanaka, Ryo; Fujita, Takayuki; Yokoyama, Utako; Taguri, Masataka; Okumura, Satoshi; Sato, Motohiko; Eguchi, Haruki; Ishikawa, Yoshihiro.
Afiliação
  • Umemura M; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: umemurma@yokohama-cu.ac.jp.
  • Kim JH; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: jeongkim@yokohama-cu.ac.jp.
  • Aoyama H; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: haruki.aoyama520@gmail.com.
  • Hoshino Y; Department of Environment and Natural Sciences, Graduate School of Environment and Information Sciences, Yokohama National University, 79-7, Tokiwada, Hodogaya, Yokohama 240-8501, Japan. Electronic address: hoshino-yujiro-hy@ynu.ac.jp.
  • Fukumura H; Fukumura Orthopedic Clinic, 1869-1 Shimokurata, Hanatachi, Yokohama 244-0815, Japan. Electronic address: sp3e7y69@piano.ocn.ne.jp.
  • Nakakaji R; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan; Department of Oral and Maxillofacial Surgery, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Elect
  • Sato I; Sato Oral and Maxillofacial Surgery Clinic, 1-6-27 2F, Zushi, Zushi 249-0006, Japan. Electronic address: itarusato0@gmail.com.
  • Ohtake M; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan; Department of Neurosurgery, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: mak
  • Akimoto T; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan; Department of Neurosurgery, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: tai
  • Narikawa M; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: n60017611@yahoo.co.jp.
  • Tanaka R; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: t166052f@yokohama-cu.ac.jp.
  • Fujita T; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: fujitaka@yokohama-cu.ac.jp.
  • Yokoyama U; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: utako@yokohama-cu.ac.jp.
  • Taguri M; Department of Biostatistics, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: taguri@yokohama-cu.ac.jp.
  • Okumura S; Tsurumi University School of Dental Medicine, 2-1-3, Tsurumi, Yokohama 230-8501, Japan. Electronic address: okumura-s@tsurumi-u.ac.jp.
  • Sato M; Department of Physiology, Aichi Medical University, 1-1, Yazakokarimata, Nagakute, Aichi 480-1103, Japan. Electronic address: motosato@aichi-med-u.ac.jp.
  • Eguchi H; Advanced Applied Science Department, Research Laboratory, IHI Corporation, Shinnakaharamachi, Isogo, Yokohama 235-8501, Japan. Electronic address: haruki_eguchi@ihi.co.jp.
  • Ishikawa Y; Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: yishikaw@med.yokohama-cu.ac.jp.
J Pharmacol Sci ; 134(4): 203-210, 2017 Aug.
Article em En | MEDLINE | ID: mdl-28779994
Iron-salen, i.e., µ-oxo-N,N'-bis(salicylidene)ethylenediamine iron (Fe(Salen)) was a recently identified as a new anti-cancer compound with intrinsic magnetic properties. Chelation therapy has been widely used in management of metallic poisoning, because an administration of agents that bind metals can prevent potential lethal effects of particular metal. In this study, we confirmed the therapeutic effect of deferoxamine mesylate (DFO) chelation against Fe(Salen) as part of the chelator antidote efficacy. DFO administration resulted in reduced cytotoxicity and ROS generation by Fe(Salen) in cancer cells. DFO (25 mg/kg) reduced the onset of Fe(Salen) (25 mg/kg)-induced acute liver and renal dysfunction. DFO (300 mg/kg) improves survival rate after systematic injection of a fatal dose of Fe(Salen) (200 mg/kg) in mice. DFO enables the use of higher Fe(Salen) doses to treat progressive states of cancer, and it also appears to decrease the acute side effects of Fe(Salen). This makes DFO a potential antidote candidate for Fe(Salen)-based cancer treatments, and this novel strategy could be widely used in minimally-invasive clinical settings.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quelantes / Quelantes de Ferro / Desferroxamina / Etilenodiaminas / Ferro / Antídotos / Antineoplásicos Tipo de estudo: Etiology_studies Limite: Animals / Humans Idioma: En Revista: J Pharmacol Sci Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quelantes / Quelantes de Ferro / Desferroxamina / Etilenodiaminas / Ferro / Antídotos / Antineoplásicos Tipo de estudo: Etiology_studies Limite: Animals / Humans Idioma: En Revista: J Pharmacol Sci Ano de publicação: 2017 Tipo de documento: Article